Hudson Bay Capital Management
ELTX icon

Hudson Bay Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Hudson Bay Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,208
Closed -$216K – 1444
2026
Q1 		$216K Buy
+20,208
New +$195K ﹤0.01% 1086
2025
Q2 		– Sell
-182,734
Closed -$1.13M – 1457
2025
Q1 		$1.13M Buy
+182,734
New +$1.42M ﹤0.01% 899
2024
Q3 		– Sell
-48,720
Closed -$200K – 919
2024
Q2 		$200K Buy
+48,720
New +$412K ﹤0.01% 663

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Hudson Bay Capital Management's ELTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 20,208 shares — an estimated $216K sold.

Hudson Bay Capital Management first reported a position in ELTX in Q2 2024 and held it in 3 quarters. The position peaked at $1.13M in Q1 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 20,208 Elicio Therapeutics shares in Q2 2026, an estimated $216K.
  • Hudson Bay Capital Management first reported a position in Elicio Therapeutics in Q2 2024 and held it in 3 quarters.
  • Hudson Bay Capital Management's Elicio Therapeutics position peaked at $1.13M in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.